Heather Wakelee, MD
Advertisement
Articles by Heather Wakelee, MD
Advertisement
Latest Updated Articles
Novel Therapy for NSCLC With EGFR Exon 20 Insertion MutationPublished: August 2nd 2022 | Updated:
Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%Published: June 25th 2024 | Updated:
- Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC
Published: June 25th 2024 | Updated:
Novel Therapy for NSCLC With ALK RearrangementsPublished: August 9th 2022 | Updated:
Is There a Role for IO Therapy in Advanced NSCLC With EGFR Mutations?Published: August 2nd 2022 | Updated:
- Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC
Published: July 12th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5